361 Capital’s Akebia Therapeutics AKBA Stock Holding History

361 Capital’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-139,489	Closed	-$2.74M	–	233
2017 Q3	$2.74M	Buy	+139,489	New	+$2.14M	0.53%	54

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

361 Capital's AKBA Position: Q4 2017 in Review

361 Capital sold out of Akebia Therapeutics (AKBA) in Q4 2017, closing a stake of 139,489 shares — an estimated $2.74M sold.

361 Capital first reported a position in AKBA in Q3 2017 and held it in 1 quarter. The position peaked at $2.74M in Q3 2017. 132 funds tracked by Wall St. Rank hold AKBA as of Q4 2017.

361 Capital reported no remaining Akebia Therapeutics position as of Q4 2017 after selling out during the quarter.
361 Capital sold 139,489 Akebia Therapeutics shares in Q4 2017, an estimated $2.74M.
361 Capital first reported a position in Akebia Therapeutics in Q3 2017 and held it in 1 quarter.
361 Capital's Akebia Therapeutics position peaked at $2.74M in Q3 2017.
132 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2017.

Based on 361 Capital's 13F filing for Q4 2017, filed 14 Feb 2018.